keyword
MENU ▼
Read by QxMD icon Read
search

Elderly, chemotherapy, lung cancer

keyword
https://www.readbyqxmd.com/read/29926550/clinical-characteristics-and-prognostic-factors-of-lung-cancer-in-korea-a-pilot-study-of-data-from-the-korean-nationwide-lung-cancer-registry
#1
Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Young Chul Kim, Jung Eun Kim, Boram Lee, Young Joo Won, Chang Min Choi
BACKGROUND: Lung cancer is a leading cause of morbidity and mortality worldwide, and the incidence continues to rise. Although many prognostic factors have been identified, the clinical characteristics and outcomes in Korean lung cancer patients are not well defined. METHODS: Of the 23,254 new lung cancer cases registered at the Korea Central Cancer Registry in 2013, total 489 patients from 19 hospitals were abstracted by the Korean Central Cancer Registry. The clinical data retrospectively analyzed, patients were followed up until December 2015...
June 19, 2018: Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29870153/comparison-of-carboplatin-plus-etoposide-with-amrubicin-monotherapy-for-extensive-disease-small-cell-lung-cancer-in-the-elderly-and-patients-with-poor-performance-status
#2
Satoshi Igawa, Masayuki Shirasawa, Takahiro Ozawa, Noriko Nishinarita, Yuriko Okuma, Taihei Ono, Ai Sugimoto, Shintaro Kurahayashi, Keisuke Sugita, Hideyuki Sone, Tomoya Fukui, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Katsuhiko Naoki
BACKGROUND: Carboplatin plus etoposide (CE) is a standard treatment for elderly patients with extensive-disease small cell lung cancer (ED-SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED-SCLC in elderly patients and chemotherapy-naive patients with poor performance status (PS). METHODS: The records of SCLC patients who received CE or AMR as first-line chemotherapy were retrospectively reviewed and their treatment outcomes evaluated...
June 5, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29861395/a-randomized-phase-iii-study-comparing-carboplatin-with-nab-paclitaxel-versus-docetaxel-for-elderly-patients-with-squamous-cell-lung-cancer-study-protocol
#3
Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose
BACKGROUND: Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older...
May 19, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29858022/impact-of-a-comprehensive-geriatric-assessment-to-manage-elderly-patients-with-locally-advanced-non-small-cell-lung-cancers-an-open-phase-ii-study-using-concurrent-cisplatin-oral-vinorelbine-and-radiotherapy-gfpc-08-06
#4
Chrystèle Locher, Nicolas Pourel, Hervé Le Caer, Henri Berard, Jean-Bernard Auliac, Isabelle Monnet, Renaud Descourt, Alain Vergnenègre, Isabelle Martel Lafay, Laurent Greillier, Christos Chouaïd
INTRODUCTION: Few data have been published on the optimal management of elderly patients with locally advanced non-small-cell lung cancers (La-NSCLC). This prospective, multicenter, phase II study was undertaken to evaluate the ability of a comprehensive geriatric assessment (CGA) to select the elderly La-NSCLC patients who potentially may benefit from concurrent radio-chemotherapy. METHODS: The main inclusion criteria were: La-NSCLC, >70 years old, at least one measurable target, ECOG performance status (PS) 0/1 and normal CGA...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29848743/phase-ii-trial-of-carboplatin-and-pemetrexed-plus-bevacizumab-with-maintenance-bevacizumab-as-a-first-line-treatment-for-advanced-non-squamous-non-small-cell-lung-cancer-in-elderly-patients
#5
MULTICENTER STUDY
Hiroaki Takeoka, Kazuhiko Yamada, Yoshiko Naito, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Koichi Azuma, Masao Ichiki, Tomoaki Hoshino
BACKGROUND/AIM: The combination of platinum-doublet chemotherapy with bevacizumab has been established as a first-line treatment option in non-elderly patients with non-squamous (non-sq) non-small cell lung cancer (NSCLC). However, the safety and efficacy of this regimen have not yet been fully established in elderly patients. PATIENTS AND METHODS: Chemo-naïve patients with non-sq NSCLC, aged ≥75 years, having a good performance status (Eastern Cooperative Oncology Group performance status 0-1) and adequate organ function were considered eligible...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29799330/greater-spending-associated-with-improved-survival-for-some-cancers-in-ocm-defined-episodes
#6
James Baumgardner, Ahva Shahabi, Mark Linthicum, Seanna Vine, Christopher Zacker, Darius Lakdawalla
BACKGROUND: Previous research finds significant variation in spending and utilization across regions, with little evidence of differences in outcomes. While such findings have been interpreted as evidence that spending can be reduced without compromising patient outcomes, the link between spending variation and outcomes remains a critical question. OBJECTIVE: To use evidence from geographic variations in spending and an individual-level survival analysis to test whether spending within oncology care episodes is associated with survival, where episodes are defined as in the Center for Medicare and Medicaid Innovation's Oncology Care Model (OCM)...
June 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29749011/rapid-lc-ms-ms-method-for-quantification-of-vinorelbine-and-4-o-deacetylvinorelbine-in-human-whole-blood-suitable-to-monitoring-oral-metronomic-anticancer-therapy
#7
Giuseppe Corona, Milena Gusella, Anna Gaspardo, Gianmaria Miolo, Laura Bertolaso, Elisa Pezzolo, Felice Pasini, Agostino Steffan, Donatella Caruso
A rapid and sensitive LC-MS/MS method for therapeutic drug monitoring oral vinorelbine (VRL) metronomic anticancer chemotherapy has been developed and validated. Analysis of VRL and its main active metabolite 4-O-deacetylvinorelbine (M1) was performed in whole blood matrix. Both analytes were extracted by protein precipitation and separated on an Onyx monolith C18 , 50 × 2 mm column then quantified by positive electrospray ionization and multiple reaction monitoring mode. The LLOQ was 0.05 ng/mL for both VRL and M1...
May 10, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29737372/efficacy-and-safety-of-cytotoxic-drug-chemotherapy-after-first-line-egfr-tki-treatment-in-elderly-patients-with-non-small-cell-lung-cancer-harboring-sensitive-egfr-mutations
#8
Hisao Imai, Hiroyuki Minemura, Tomohide Sugiyama, Yutaka Yamada, Kyoichi Kaira, Kenya Kanazawa, Takashi Kasai, Takayuki Kaburagi, Koichi Minato
PURPOSE: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is effective as first-line chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, whether the efficacy of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment is similar to that of first-line cytotoxic drug chemotherapy in elderly patients aged ≥ 75 years harboring sensitive EGFR mutations is unclear. Therefore, we aimed to investigate the efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations...
July 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29656745/severe-adverse-events-impact-overall-survival-and-costs-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-on-second-line-therapy
#9
Hossein Borghaei, Yeun Mi Yim, Annie Guerin, Irina Pivneva, Sherry Shi, Mayank Gandhi, Raluca Ionescu-Ittu
OBJECTIVES: Elderly patients with advanced non-small lung cancer (aNSCLC) represent a high-risk patient population due to disease burden, comorbidities, and performance status, particularly after progressing on first-line therapy. Among elderly patients who receive second-line therapy, treatment related toxicities can have substantial impact on both clinical and economic outcomes. This study assessed the impact of severe adverse events (AEs) during second-line therapy on overall survival (OS) and all-cause heathcare costs in elderly with aNSCLC...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29650844/-super-elderly-recurrent-rectal-cancer-effectively-treated-with-chemotherapy-for-three-years-report-of-a-case
#10
Yasuaki Miyazaki, Kazuo Yamabe, Nobuyasu Hayashi, Toshiya Michiura, Tomo Nakagawa, Satoshi Hyuga, Tomotaka Murotani, Makio Nagaoka
The safety and feasibility of the chemotherapy for super-elderly patients over 85 years old have not been clarified yet. We report an extremely aged patient with recurrent rectal cancer that was successfully treated with chemotherapy. A 85-year-old woman underwent Hartmann procedure for rectal cancer. Nine months after surgery, CT scan revealed liver metastases in S5 and S7. We administered capecitabine plus bevacizumab chemotherapy. Liver metastases were disappeared after 6 courses. Although grade 2 hypertension was appeared, no other adverse event occurred...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650688/outcomes-of-elderly-patients-with-advanced-soft-tissue-sarcoma-treated-with-first-line-chemotherapy-a-pooled-analysis-of-12-eortc-soft-tissue-and-bone-sarcoma-group-trials
#11
Eugenie Younger, Saskia Litière, Axel Le Cesne, Olivier Mir, Hans Gelderblom, Antoine Italiano, Sandrine Marreaud, Robin Lewis Jones, Alessandro Gronchi, Winette T A van der Graaf
BACKGROUND: Almost half of patients diagnosed with soft tissue sarcoma (STS) are older than 65 years; however, the outcomes of elderly patients with metastatic disease are not well described. PATIENTS AND METHODS: An elderly cohort of patients aged ≥65 years was extracted from the European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group database of patients treated with first-line chemotherapy for advanced STS within 12 EORTC clinical trials...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29587656/erlotinib-treatment-after-platinum-based-therapy-in-elderly-patients-with-non-small-cell-lung-cancer-in-routine-clinical-practice-results-from-the-eldertac-study
#12
Wolfgang M Brueckl, H Jost Achenbach, Joachim H Ficker, Wolfgang Schuette
BACKGROUND: In this prospective non-interventional study, the effectiveness and tolerability of erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after ≥1 platinum-based chemotherapy were assessed. METHODS: A total of 385 patients ≥65 years of age with advanced NSCLC receiving erlotinib were observed over 12 months. The primary endpoint was the 1-year overall survival (OS) rate. RESULTS: Patients were predominantly Caucasian (99...
March 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29572782/a-phase-i-ii-trial-of-pemetrexed-plus-radiotherapy-in-elderly-patients-with-locally-advanced-non-small-cell-lung-cancer
#13
Akihiro Tamiya, Masahiro Morimoto, Shoichi Fukuda, Yoko Naoki, Tatsuya Ibe, Kyoichi Okishio, Hideto Goto, Akihiro Yoshii, Toshiyuki Kita, Naoyuki Nogami, Yuka Fujita, Shinji Atagi
Background Radiotherapy (RT) is an effective treatment for elderly patients with locally advanced non-small-cell lung cancer (NSCLC); however, no clinical trials have investigated combination RT with pemetrexed (PEM) in chemotherapy-naive patients ≥71 years old. We conducted a phase I/II study to evaluate the appropriate PEM dose, efficacy, and safety of PEM plus RT in elderly patients. Methods Patients ≥71 years with performance status (PS) scores of 0-2 who had pathologically confirmed stage IIIA/IIIB NSCLC received PEM (500 mg/m2 on day 1 of a 28-day cycle, 4 courses) and RT (a single 2 Gy daily fraction on 5 consecutive days weekly from day 1; 60 Gy total)...
March 23, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29552767/toxicity-and-efficacy-of-a-hypofractionated-3-weekly-fractions-of-850c-gy-irradiation-schedule-for-stage-iiib-iv-non-small-cell-lung-cancer-elderly-patients-with-low-performance-status-and-unfit-for-chemotherapy
#14
Vassilis Kouloulias, Evridiki Patriki, Eftychia Mosa, Kalliopi Platoni, John Georgakopoulos, Anna Zygogianni, Maria Dilvoi, George Patatoukas, Christos Antypas, Christina Armpilia, Nikolaos Trogkanis, Eyfrosini Kypraiou, Stella Nikoloudi, George Giannakouras, Efstathios Efstathopoulos, Nikolaos Kelekis, John Kouvaris
PURPOSE: To evaluate in an observational way the clinical impact of a hypofractionated irradiation schedule in patients with unresectable non-small cell lung cancer (NSCLC). METHODS: Forty elderly patients (24 men/16 women) diagnosed with unresectable stage IIIb/IV NSCLC unfit for chemotherapy, were treated with once-a-week hypofractionation schedule. All patients had a poor performance status. A dose of 255 Gy in 3 weekly fractions was prescribed while a 3D conformal technique (3D-CRT) was used for irradiation...
January 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29458244/clinical-and-molecular-characteristics-of-pulmonary-sarcomatoid-carcinoma
#15
Jae Kyeom Sim, Sang Mi Chung, Jong Hyun Choi, Jee Youn Oh, Seung Heon Lee, Je Hyeong Kim, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Bong Kyung Shin, Ju Han Lee, Sung Yong Lee
Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes...
February 20, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29393275/efficacy-of-platinum-based-chemotherapy-for-relapsed-small-cell-lung-cancer-after-amrubicin-monotherapy-in-elderly-patients-and-patients-with-poor-performance-status
#16
Satoshi Igawa, Masayuki Shirasawa, Tomoya Fukui, Noriko Nishinarita, Hideyuki Sone, Takahiro Ozawa, Keisuke Sugita, Yuriko Okuma, Shintaro Kurahayashi, Taihei Ono, Ai Sugimoto, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Katsuhiko Naoki
BACKGROUND: Previous studies have shown amrubicin to be an effective first- or second-line treatment option for small-cell lung cancer (SCLC). However, there have been few studies reporting the efficacy of platinum-based chemotherapy after amrubicin therapy. We aimed to evaluate the efficacy of platinum-based chemotherapy as second-line treatment for elderly patients and those with SCLC with poor performance status (PS) previously treated with amrubicin monotherapy. METHODS: The records of SCLC patients who received platinum-based chemotherapy as a second-line chemotherapy after first-line treatment with amrubicin monotherapy were retrospectively reviewed and the treatment outcomes were evaluated...
2018: Oncology
https://www.readbyqxmd.com/read/29391891/efficacy-of-second-line-treatment-and-importance-of-comorbidity-scores-and-clinical-parameters-affecting-prognosis-in-elderly-patients-with-non-small-cell-lung-cancer-without-epidermal-growth-factor-receptor-mutations
#17
Sung Yong Lee, Eun Joo Kang, Suk Young Lee, Hong Jun Kim, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Sang Cheul Oh, Jae Hong Seo, Jun Suk Kim
The present study investigated the importance of comorbidity scores and clinical parameters in elderly patients with non-small cell lung cancer (NSCLC) not harboring epidermal growth factor receptor ( EGFR ) mutations who received second-line chemotherapy. The present study also compared the efficacy of tyrosine kinase inhibitor and cytotoxic chemotherapy as second-line treatment in elderly patients. The present study retrospectively reviewed the treatment of elderly patients with NSCLC (≥70 years old) who received second-line chemotherapy at Korea University Guro Hospital...
January 2018: Oncology Letters
https://www.readbyqxmd.com/read/29390380/significant-efficacy-and-well-safety-of-apatinib-combined-with-radiotherapy-in-nsclc-case-report
#18
Chunbo Zhao, Qian Zhang, Wenbo Qiao
RATIONALE: The outcomes of locally advanced non-small cell lung cancer (NSCLC) remain poor, in particular, the frail elderly patients cannot tolerate chemotherapy. The new efficient, safe, and more specific treatments are needed. Radiation combined with targeted therapy is the focus of research in recent years. Apatinib is highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, studies have revealed that apatinib inhibit the growth of solid tumors including NSCLC...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29381689/geriatric-assessment-may-help-decision-making-in-elderly-patients-with-inoperable-locally-advanced-non-small-cell-lung-cancer
#19
Maite Antonio, Juana Saldaña, Jennifer Linares, José C Ruffinelli, Ramón Palmero, Arturo Navarro, Maria Dolores Arnaiz, Isabel Brao, Samantha Aso, Susana Padrones, Valentí Navarro, Jesús González-Barboteo, Josep Maria Borràs, Felipe Cardenal, Ernest Nadal
BACKGROUND: Although concurrent chemoradiotherapy (cCRT) increases survival in patients with inoperable, locally advanced non-small-cell lung cancer (NSCLC), there is no consensus on the treatment of elderly patients. The aim of this study was to determine the prognostic value of the comprehensive geriatric assessment (CGA) and its ability to predict toxicity in this setting. METHODS: We enrolled 85 consecutive elderly (⩾75 years) participants, who underwent CGA and the Vulnerable Elders Survey (VES-13)...
March 6, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29362308/-an-elderly-patient-with-metastatic-colon-cancer-achieved-long-term-survival-following-single-agent-chemotherapy-with-s-1
#20
Yuta Muto, Kentaro Chochi, Daisaku Morita, Atsuo Oka, Toshiki Rikiyama
Colorectal cancer is a common malignancy and a major health issue in geriatrics. Systemic chemotherapy should be considered for elderly patients. We report an 85-year-old man with metastatic cecal cancer who has achieved long-term survival following single-agent chemotherapy with S-1. His fecal occult blood test results were positive; he then underwent colonoscopy and was diagnosed with cecal cancer. Chest CT revealed multiple metastases in both lungs. Since radical excision was infeasible, we performed right hemicolectomy to prevent bowel obstruction...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
109146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"